newsfilter
← Latest News
Business Wire·

Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide

Milestone underscores test's significant role as a global standard-of-care in guiding personalized breast cancer treatment The predictive utility of this test helped an estimated 1.6 million patients safely avoid